



Annual and Special Meeting of Shareholders

June 20, 2017

CR  SCITA
S K I N S C I E N C E S



Daniel Chicoine, Chairman

CR  SCITA
S K I N S C I E N C E S

Agenda

- Call to Order
- Business Matters:
 - Notice of Meeting and Quorum
 - Presentation of 2016 Restated Consolidated Financial Statements
 - Nomination and Election of Directors
 - Appointment of Auditors
 - Approval of Base Consideration Shares
 - Approval of Milestone Shares
 - Other Business
- Management Presentation
- Voting Results
- Termination of Formal Business
- Q&A



Formal Business

CR  SCITA
S K I N S C I E N C E S

Nomination of the Directors of the Corporation

The following persons are nominated for election as Directors of the Corporation:

Daniel Chicoine

David Copeland

Anthony Dobranowski

John London

Samira Sakhia

Thomas Schlader

Resolution – Election of Directors

RESOLVED that Daniel Chicoine, David Copeland, Anthony Dobranowski, John London, Samira Sakhia and Thomas Schlader are nominated as directors of the Corporation to hold office until the next annual meeting of shareholders, until their successors are duly elected or appointed or they otherwise cease to hold office.

Resolution – Auditors

RESOLVED that Ernst & Young LLP, Chartered Accountants, be reappointed as the Auditors of the Corporation, to hold office until the next Annual Meeting of Shareholders or until a successor is appointed and that the Directors be authorized to fix their remuneration.

Resolution – Base Consideration Shares

RESOLVED that the resolution set forth in Schedule A of the management information circular, authorizing the Corporation to issue up to 713,214 common shares of the Corporation pursuant to Section 2.3 of the Purchase Agreement with respect to the acquisition of INTEGA Skin Sciences Inc. by the Corporation, be passed.

Resolution – Milestone Shares

RESOLVED that the resolution set forth in Schedule B of the management information circular, authorizing the Corporation to issue such number of common shares as is required in satisfaction of any payment that becomes due pursuant to Section 2.8 of the Purchase Agreement, be passed.

Other Business



Management Presentation

CR  SCITA
S K I N S C I E N C E S

Safe Harbour

Certain information to be discussed during this corporate update contains forward-looking statements within the meaning of applicable securities laws including, among others, statements concerning the Company's 2017 objectives, the Company's strategies to achieve those objectives, as well as statements with respect to Management's beliefs, plans, estimates, and intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts.

Such forward-looking statements reflect Management's current beliefs as of the date hereof and are based on information currently available to Management.

These statements are not guarantees of future performance and are based on the Company's estimates and assumptions and are subject to risks and uncertainties, including those described in the Company's Management Discussion and Analysis regarding the 2016 annual audited financial statements and news releases, which could cause the Company's actual results to differ materially from the forward-looking statements to be discussed during this presentation.

Although the forward-looking information discussed during this presentation is based upon what Management believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements.

Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Introduction & Highlights

Market

- Opportunity exists for mid-size companies to capture market share by offering differentiated high quality products
- Skincare market dominated by large derm companies (Allergan, Galderma, Valeant, etc.)
- Consumer demand for science-based skincare products growing in both prescription and non-prescription skincare markets

Fully Integrated

- Crescita is an integrated skincare company focused on delivering innovative products for both the prescription and non-prescription skincare markets

Crescita – Capabilities and Advantages

Products

- Specialized dermatology products with superior formulations
- Diversified portfolio of both prescription and non-prescription products
- Strong brands across a range of sales channels and markets

Technologies

- Innovative technologies for delivery of active ingredients/drugs through the skin

Infrastructure

- Full sales and marketing infrastructure servicing spa and medispa markets
- Full manufacturing capabilities
- Significant capacity and well positioned for future revenue growth and profitability



Non-Prescription Skincare Products

CR  SCITA
S K I N S C I E N C E S

Non-Prescription Skincare Products



Products – Aesthetics Professional Kits

Channel – Professional Aesthetic Spas



Products – Medical Skin Care Products

Channel – Medical Spas



Products – Medical Skin Care Products

Channel – Medical Spas & Pharmacies

The logo for premiology 360 features the word "premiology" in a grey, lowercase, sans-serif font, followed by "360" in a red, lowercase, sans-serif font.

Products – High End Aesthetics products

Channel – Professional Aesthetic Spas

Potential International Out-Licensing Opportunities

Laboratoire Dr Renaud, Pro-Derm and Premiology



■ Available for out-licensing *

■ Launched

* LDR trademark available in selected countries

Non-Prescription Skincare Products Growth Strategy – 4 Pillars



Organic growth of existing product lines



Strategic acquisitions of products and/or companies



Further develop in international markets



Grow CMO business



Prescription Drug Products

CR  SCITA
S K I N S C I E N C E S

Prescription Drug Products

Proprietary Technology Platforms

Topical and Transdermal Drug Delivery

MMPE™

Multiplexed Molecular
Penetration Enhancers


- Combinations of FDA approved excipients to deliver actives into or through the skin

Peel & DuraPeel

Phase-Changing
Topical Cream

- Phase-changing cream using self-occlusion to deliver actives into or through the skin

Prescription Drug Products – Development Stage



Prescription Drug Products – Pliaglis/Flexicaine

- Provides topical local analgesia for superficial dermatological and cosmetic procedures
- Reliable and long-lasting anesthetic effect from highest strength approved formulation
- Rights reacquired for the U.S., Canada and Mexico where product is approved (U.S. rights sold to Tara Pharmaceuticals – April 2017)
- Flexicaine is next generation version of Pliaglis with patents to 2031



Lidocaine and tetracaine (7%/7%) proprietary phase-changing, peelable cream

Prescription Drug Products

Pliaglis – Licensing Developments

Country	Licensee	Terms
Canada	Crescita	Sold through existing channels
U.S.	Taro Pharmaceuticals	Royalties and Milestones
Mexico	Available	In discussions
ROW	Galderma	Single digit royalty

Prescription Drug Products – MiCal Co-Development Products

- Collaboration with MiCal
 - MiCal is a JV between Ferndale and a leading CRO
- Targets development of two dermatology products
- Crescita responsible for formulation development/IP which include patented MMPE technology
- MiCal will fund Phase 2 clinical development of products
- Economics to be shared between parties



Prescription Drug Products – Revenue Potential

- The three Crescita owned Rx products represent significant revenue potential from milestones and royalties
- The total of the negotiated one time milestone payments could exceed \$6.5 million
- The Global royalty stream from Pliaglis could exceed \$4.0 million per year
- Pliaglis rights for Mexico and Canada, in addition to MiCal out-licensing deals, could provide further revenue potential






Q1 Financial Information

CR  SCITA
S K I N S C I E N C E S


Q1 2017 Performance

CDN\$ Millions




Q1 2017 vs Q1 2016 Performance – Net Loss

CDN\$ Millions



Cash & Short-term Investments*




*\$8.6 million is restricted cash, held in short-term investments, guaranteeing the Knight loan



Future Growth Strategy

CR  SCITA
S K I N S C I E N C E S

Sources of Revenue Growth



Upcoming Milestones

Focused BD activities to in-license/acquire new products → Already in discussion on multiple opportunities	Ongoing
Completion of MiCal formulation development – 2nd product	Q2 2017
MiCal Phase 2 Trial results – 1 st product	Q3 2017
Begin Pliaglis trial to remove “Not for Home Use” label	H2 2017
Begin filings & process to approve Pliaglis “Enhanced Formulation”	H2 2017
Out-licensing of Pliaglis for Mexican market	2018
Launch Pliaglis in Canada	2018
Re-launch Pliaglis in U.S. market	2018
Licensing MiCal 1	2018

Financial Snapshot

Stock Symbol	TSX: CTX
Market Cap (June 15/17)	\$11.4 million \$0.82 share price
Shares Outstanding	13.9
Fully Diluted Shares Outstanding	16.8
Share Price Low-High	\$0.82 - \$1.99
Cash and Short-term Investments*	\$13.8 million
Debt (March 31, 2017)	\$8.1 million
Headquarters	Mississauga, ON
Manufacturing	Laval, QC

*\$8.6 million is restricted cash, held in short-term investments, guaranteeing the loan and \$5.2 million is cash available for operations

Investment Highlights

Crescita represents an excellent investment opportunity:

Low Share Price

- Currently trading at cash value

Growth

- Non-prescription business well positioned for domestic and international growth
 - CMO business is growing
 - RX products about to launch or out-license - Within maximum two years, Pliaglis annual minimum royalty revenue guaranteed at approximately \$1.0 million/year with global upside exceeding \$4.4 million/year
 - Other prescription products to be out-licensed
 - Numerous “tuck-in” acquisitions being considered



Proxy Vote Count

CR  SCITA
S K I N S C I E N C E S

Proxy Vote Count – Election of Directors

	For %	Withheld %
Elect Directors		
• Daniel Chicoine	95.71	4.29
• David Copeland	96.15	3.85
• Anthony Dobranowski	96.36	3.64
• John London	95.72	4.28
• Samira Sakhia	96.79	3.21
• Thomas Schlader	96.60	3.40

Proxy Vote Count – Appointment of Auditors

	For %	Withheld %
Appointment of Auditors	95.90	4.10

Proxy Vote Count – Approval of Base Consideration Shares

	For %	Against %
Approval of Base Consideration Shares	95.17	4.83

Proxy Vote Count – Approval of Milestone Shares

	For %	Against %
Approval of Milestone Shares	94.98	5.02

Resolution - Terminate the Meeting

RESOLVED that the Annual Meeting of Shareholders for 2017 terminate.



Q&A

CR  **SCITA**
S K I N S C I E N C E S